AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a New Drug Pipeline
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a New Drug Pipeline
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a New Drug Pipeline
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland, MSc
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland, MSc
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland, MSc
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.